{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.2","upperLimit":"40.9","value":"24.7"},{"comment":"Not calculable/estimable due to low number of participants with events","groupId":"OG001","lowerLimit":"20.1","upperLimit":"NA","value":"43.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"description":"PFS is defined as the number of days from the date of first dose to the date of earliest disease progression (PD) or death. PFS was analyzed by Kaplan-Meier methodology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with ibrutinib-resistant or refractory chronic lymphocytic leukemia (CLL) in the Main and Expansion Cohorts","id":"OG000","title":"ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts"},{"description":"Participants with idelalisib-resistant or refractory chronic lymphocytic leukemia (CLL) in the Main and Expansion Cohorts","id":"OG001","title":"ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts"}],"paramType":"MEDIAN","populationDescription":"All enrolled participants who received venetoclax and had active disease at baseline","reportingStatus":"POSTED","timeFrame":"At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}